BioCryst Pharmaceuticals (BCRX) Revenue & Revenue Breakdown
BioCryst Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$331.41M
Latest Revenue (Q)
$109.33M
Main Segment (Y)
Product
BioCryst Pharmaceuticals Revenue by Period
BioCryst Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $331.41M | 22.37% |
| 2022-12-31 | $270.83M | 72.31% |
| 2021-12-31 | $157.17M | 782.38% |
| 2020-12-31 | $17.81M | -63.53% |
| 2019-12-31 | $48.84M | 136.45% |
| 2018-12-31 | $20.65M | -18.00% |
| 2017-12-31 | $25.19M | -4.43% |
| 2016-12-31 | $26.35M | -45.39% |
| 2015-12-31 | $48.26M | 254.62% |
| 2014-12-31 | $13.61M | -21.48% |
| 2013-12-31 | $17.33M | -34.09% |
| 2012-12-31 | $26.29M | 33.85% |
| 2011-12-31 | $19.64M | -69.07% |
| 2010-12-31 | $63.50M | -14.87% |
| 2009-12-31 | $74.59M | 31.87% |
| 2008-12-31 | $56.56M | -20.60% |
| 2007-12-31 | $71.24M | 1046.79% |
| 2006-12-31 | $6.21M | 3990.38% |
| 2005-12-31 | $151.87K | -54.92% |
| 2004-12-31 | $336.90K | -79.38% |
| 2003-12-31 | $1.63M | -7.92% |
| 2002-12-31 | $1.77M | -84.10% |
| 2001-12-31 | $11.16M | 236.52% |
| 2000-12-31 | $3.32M | 32.62% |
| 1999-12-31 | $2.50M | -60.94% |
| 1998-12-31 | $6.40M | 540.00% |
| 1997-12-31 | $1.00M | -62.96% |
| 1996-12-31 | $2.70M | 1250.00% |
| 1995-12-31 | $200.00K | -71.43% |
| 1994-12-31 | $700.00K | - |
BioCryst Pharmaceuticals generated $331.41M in revenue during NA 2023, up 22.37% compared to the previous quarter, and up 1604.67% compared to the same period a year ago.
BioCryst Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $109.33M | 17.86% |
| 2024-03-31 | $92.76M | -0.69% |
| 2023-12-31 | $93.40M | 7.68% |
| 2023-09-30 | $86.74M | 5.15% |
| 2023-06-30 | $82.49M | 19.94% |
| 2023-03-31 | $68.78M | -13.54% |
| 2022-12-31 | $79.55M | 4.90% |
| 2022-09-30 | $75.83M | 15.71% |
| 2022-06-30 | $65.53M | 31.27% |
| 2022-03-31 | $49.92M | 5.86% |
| 2021-12-31 | $47.16M | 15.04% |
| 2021-09-30 | $40.99M | -17.94% |
| 2021-06-30 | $49.96M | 162.13% |
| 2021-03-31 | $19.06M | 374.58% |
| 2020-12-31 | $4.02M | -34.19% |
| 2020-09-30 | $6.10M | 112.54% |
| 2020-06-30 | $2.87M | -40.47% |
| 2020-03-31 | $4.82M | -87.86% |
| 2019-12-31 | $39.73M | 2138.03% |
| 2019-09-30 | $1.77M | 22.58% |
| 2019-06-30 | $1.45M | -75.40% |
| 2019-03-31 | $5.89M | 115.72% |
| 2018-12-31 | $2.73M | 87.69% |
| 2018-09-30 | $1.45M | -88.36% |
| 2018-06-30 | $12.49M | 214.24% |
| 2018-03-31 | $3.98M | 2.21% |
| 2017-12-31 | $3.89M | -55.59% |
| 2017-09-30 | $8.76M | 182.67% |
| 2017-06-30 | $3.10M | -67.16% |
| 2017-03-31 | $9.44M | 5.05% |
| 2016-12-31 | $8.98M | 15.72% |
| 2016-09-30 | $7.76M | 62.17% |
| 2016-06-30 | $4.79M | -0.68% |
| 2016-03-31 | $4.82M | 4.74% |
| 2015-12-31 | $4.60M | -58.11% |
| 2015-09-30 | $10.99M | -57.48% |
| 2015-06-30 | $25.84M | 278.58% |
| 2015-03-31 | $6.83M | 25.34% |
| 2014-12-31 | $5.45M | 68.19% |
| 2014-09-30 | $3.24M | 120.87% |
| 2014-06-30 | $1.47M | -57.61% |
| 2014-03-31 | $3.46M | -67.28% |
| 2013-12-31 | $10.57M | 342.32% |
| 2013-09-30 | $2.39M | 190.99% |
| 2013-06-30 | $821.00K | -76.90% |
| 2013-03-31 | $3.55M | -13.34% |
| 2012-12-31 | $4.10M | -28.81% |
| 2012-09-30 | $5.76M | 36.84% |
| 2012-06-30 | $4.21M | -65.55% |
| 2012-03-31 | $12.22M | 133.94% |
| 2011-12-31 | $5.22M | -0.48% |
| 2011-09-30 | $5.25M | 40.54% |
| 2011-06-30 | $3.73M | -31.28% |
| 2011-03-31 | $5.43M | -67.44% |
| 2010-12-31 | $16.69M | 39.12% |
| 2010-09-30 | $12.00M | 57.56% |
| 2010-06-30 | $7.62M | -70.79% |
| 2010-03-31 | $26.07M | -52.51% |
| 2009-12-31 | $54.90M | 420.43% |
| 2009-09-30 | $10.55M | 120.35% |
| 2009-06-30 | $4.79M | 9.82% |
| 2009-03-31 | $4.36M | -87.27% |
| 2008-12-31 | $34.24M | 284.98% |
| 2008-09-30 | $8.89M | 234.49% |
| 2008-06-30 | $2.66M | -75.31% |
| 2008-03-31 | $10.77M | -61.78% |
| 2007-12-31 | $28.17M | - |
BioCryst Pharmaceuticals generated $109.33M in revenue during Q2 2024, up 17.86% compared to the previous quarter, and up 158.96% compared to the same period a year ago.
BioCryst Pharmaceuticals Revenue Breakdown
BioCryst Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $324.70M | $267.71M | $17.53M | - | - |
| Collaborative And Other Research And Development | $6.72M | $214.00K | - | - | - |
| Milestone | - | - | - | - | - |
| Collaborative and Other Research and Development | - | - | $5.92M | $25.00M | - |
| Service | - | - | - | $757.00K | - |
| Royalty | - | - | - | - | $6.30M |
BioCryst Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (97.97%), and Collaborative And Other Research And Development (2.03%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative and Other Research and Development | $3.49M | $1.45M | $1.99M | $612.00K | $14.00K | $104.00K | $30.00K | $903.00K | $1.53M | $1.40M | $2.08M | $2.27M | $3.37M | $2.83M | $2.66M | $21.43M | $932.00K | $752.00K | - | - |
| Product | $89.27M | $239.41M | $85.29M | $78.06M | $75.21M | $64.89M | $605.00K | $2.48M | - | $218.00K | $15.52M | $335.00K | - | - | - | - | - | - | - | - |
| Royalty | - | - | - | - | - | $1.42M | $600.00K | $540.00K | $1.14M | $254.00K | $44.00K | $1.95M | $2.78M | $508.00K | $696.00K | - | - | - | - | - |
| Collaborative And Other Research And Development | - | - | - | - | - | $66.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Milestone Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
BioCryst Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (96.24%), and Collaborative and Other Research and Development (3.76%).
BioCryst Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| BCRX | BioCryst Pharmaceuticals | $331.41M | $109.33M |
| AXSM | Axsome Therapeutics | $270.60M | $87.17M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| TGTX | TG Therapeutics | $233.66M | $73.47M |
| MCRB | Seres Therapeutics | $126.33M | - |
| PIRS | Pieris Pharmaceuticals | $42.81M | - |
| ATRA | Atara Biotherapeutics | $8.57M | $28.64M |
| KZR | Kezar Life Sciences | $7.00M | - |
| KRTX | Karuna Therapeutics | $654.00K | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| VKTX | Viking Therapeutics | - | - |
| PDSB | PDS Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| BIVI | BioVie | - | - |
| SAVA | Cassava Sciences | - | - |
| CGTX | Cognition Therapeutics | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| IMUX | Immunic | - | - |
| AVXL | Anavex Life Sciences | - | - |
| INMB | INmune Bio | $-155.00K | - |
BCRX Revenue FAQ
What is BioCryst Pharmaceuticals’s yearly revenue?
BioCryst Pharmaceuticals's yearly revenue for 2023 was $331.41M, representing an increase of 22.37% compared to 2022. The company's yearly revenue for 2022 was $270.83M, representing an increase of 72.31% compared to 2021. BCRX's yearly revenue for 2021 was $157.17M, representing an increase of 782.38% compared to 2020.
What is BioCryst Pharmaceuticals’s quarterly revenue?
BioCryst Pharmaceuticals's quarterly revenue for Q2 2024 was $109.33M, a 17.86% increase from the previous quarter (Q1 2024), and a 32.54% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $92.76M, a -0.69% decrease from the previous quarter (Q4 2023), and a 34.87% increase year-over-year (Q1 2023). BCRX's quarterly revenue for Q4 2023 was $93.4M, a 7.68% increase from the previous quarter (Q3 2023), and a 17.42% increase year-over-year (Q4 2022).
What is BioCryst Pharmaceuticals’s revenue growth rate?
BioCryst Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 110.86%, and for the last 5 years (2019-2023) was 578.64%.
What are BioCryst Pharmaceuticals’s revenue streams?
BioCryst Pharmaceuticals's revenue streams in c 23 are Product, and Collaborative And Other Research And Development. Product generated $324.7M in revenue, accounting 97.97% of the company's total revenue, up 21.29% year-over-year. Collaborative And Other Research And Development generated $6.72M in revenue, accounting 2.03% of the company's total revenue, up 3038.32% year-over-year.
What is BioCryst Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of BioCryst Pharmaceuticals was Product. This segment made a revenue of $324.7M, representing 97.97% of the company's total revenue.